Subsidiary of Shanghai Pharmaceuticals Holding (601607.SH) plans to publicly list and sell a 41% stake in ShangYiPharm (Shanghai) Co., Ltd.

Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary Shanghai Pharma Holding Co., Ltd. intends to transfer 41% equity of its controlled subsidiary Shanghai Yiyao Medicine Co., Ltd. through a public listing on the property rights exchange. The listed transfer price is set at 330 million yuan (final price shall not be lower than the valuation value approved by the state-owned assets evaluation), and the final transfer price will be based on the results of the public listing. After this transaction is completed, Shanghai Pharmaceuticals Holding will hold a 10% stake in the target company through Shanghai Pharma Holding and will no longer consolidate the target company. This transaction is an important strategic move for Shanghai Pharmaceuticals Holding to promote the overall development of its new retail business and further enhance its overall competitiveness. The aim is to integrate professional pharmacy resources within the Shanghai Pharmaceuticals Holding system to comprehensively enhance its market value and core competitiveness.